Patent details

301260 Product Name: Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301260
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP3355889
Status:
SPC granted but not yet in force
Application number:
301260
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1613
Marketing Authorization Type:
EEA
Marketing Authorization Date:
20/09/2023
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
04/03/2024
First Marketing Authorization date:
20/09/2023
Grant date:
25/03/2024
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
05/03/2024
SPC/SPC Extension Expiration Date:
19/09/2038
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
04/03/2024
 
 

 

Name:
Afferent Pharmaceuticals Inc.
Address:
126 East Lincoln Avenue, 07065, Rahway, New Jersey, United States of America (US)

Agent

Name:
dr. R.C. van Duijvenbode c.s.
From:
04/03/2024
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC
Journal edition number:
13/24
Publication date:
27/03/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

2

Bulletin Heading:
SPC
Journal edition number:
10/24
Publication date:
06/03/2024
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Annual Fee

Annual Fee(s) Due Date:
30/09/2036
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type
25/03/2024 Outgoing Correspondence Decision grant 1 PDF /2/4/7/5/7/0800975742/docs/301260_0_597923l504a.pdf
25/03/2024 Certificate Certificate 1 PDF /2/4/7/5/7/0800975742/docs/301260_1_spcmedcertificate20240325100445642.pdf
05/03/2024 Outgoing Correspondence Confirmation receipt request 2 PDF /2/4/7/5/7/0800975742/docs/301260_8_595267l174.pdf
04/03/2024 SPC Documents Annex SPC 2 PDF /2/4/7/5/7/0800975742/docs/301260_2_supplprotectioncertificate20240305124828996.pdf
04/03/2024 SPC Documents Annex SPC 16 PDF /2/4/7/5/7/0800975742/docs/301260_3_supplprotectioncertificate20240305124829013.pdf
04/03/2024 SPC Documents Annex SPC 3 PDF /2/4/7/5/7/0800975742/docs/301260_4_supplprotectioncertificate20240305124904758.pdf
04/03/2024 Application Form First filed application form 2 PDF /2/4/7/5/7/0800975742/docs/301260_5_applicationform20240305124559952.pdf
04/03/2024 SPC Documents Summary of the characteristics of the product 13 PDF /2/4/7/5/7/0800975742/docs/301260_6_supplprotectioncertificate20240305124828982.pdf
04/03/2024 SPC Documents Marketing Authorization SPC 3 PDF /2/4/7/5/7/0800975742/docs/301260_7_supplprotectioncertificate20240305010125655.pdf